Cybin Inc. Prices $50M Underwritten Offering to Fund Clinical Trials

summarizeSummary

Cybin Inc. announced the pricing of a $50 million underwritten offering at $4.85 per share, providing critical funding for its HLP003 Phase 3 clinical trial and other drug development programs, despite significant shareholder dilution.

check_boxKey Events

• Underwritten Offering Priced

  Cybin Inc. finalized an underwritten offering of 10,309,280 common shares at an offering price of US$4.85 per share, raising aggregate gross proceeds of US$50 million. The offering is expected to close on June 25, 2026.

• Substantial Share Dilution

  The offering will result in significant dilution for existing shareholders, with approximately 10.3 million new shares being issued against a current outstanding share count of approximately 51.7 million shares.

• Funding for Clinical Pipeline

  The net proceeds from the offering are intended to progress the company's HLP003 Phase 3 clinical trial for Major Depressive Disorder, HLP004 for Generalized Anxiety Disorder, HLP005 programs, and for general working capital.

• Phase 3 Trial Progress Update

  The company also reported that its HLP003 Phase 3 clinical trial for Major Depressive Disorder has surpassed 86% enrollment, with topline data expected in the fourth quarter of 2026. This update was previously announced.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of a significant $50 million underwritten offering, initiated on June 23, 2026. The offering is priced at a discount to the current market price and will result in substantial dilution for existing shareholders. However, this capital infusion is crucial for advancing the company's HLP003 Phase 3 clinical trial for Major Depressive Disorder, which recently surpassed 86% enrollment, as well as other key pipeline programs. This funding provides essential runway for a clinical-stage biotech to progress its drug development.